BRPI0210317B8 - complexo de vacina terapêutica destinado à prevenção ou ao tratamento de leishmanioses e infecções mediadas por microorganismos patogênicos intracelulares nos mamíferos - Google Patents

complexo de vacina terapêutica destinado à prevenção ou ao tratamento de leishmanioses e infecções mediadas por microorganismos patogênicos intracelulares nos mamíferos

Info

Publication number
BRPI0210317B8
BRPI0210317B8 BRPI0210317A BR0210317A BRPI0210317B8 BR PI0210317 B8 BRPI0210317 B8 BR PI0210317B8 BR PI0210317 A BRPI0210317 A BR PI0210317A BR 0210317 A BR0210317 A BR 0210317A BR PI0210317 B8 BRPI0210317 B8 BR PI0210317B8
Authority
BR
Brazil
Prior art keywords
leishmaniasis
mammals
prevention
treatment
pathogenic microorganisms
Prior art date
Application number
BRPI0210317A
Other languages
English (en)
Other versions
BRPI0210317C1 (pt
BRPI0210317B1 (pt
BR0210317A (pt
Inventor
Papierok Gérard
Lemesre Jean-Loup
Vicens Serge
Original Assignee
Bio Veto Tests Abreviadamente Bvt Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Veto Tests Abreviadamente Bvt Sarl filed Critical Bio Veto Tests Abreviadamente Bvt Sarl
Publication of BR0210317A publication Critical patent/BR0210317A/pt
Publication of BRPI0210317B1 publication Critical patent/BRPI0210317B1/pt
Publication of BRPI0210317B8 publication Critical patent/BRPI0210317B8/pt
Publication of BRPI0210317C1 publication Critical patent/BRPI0210317C1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Fodder In General (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

"complexo de vacina terapêutica destinado à prevenção ou ao tratamento de leishmanioses e infecções mediadas por microorganismos patogênicos intracelulares nos mamíferos". complexo de vacina terapêutica destinado à prevenção ou ao tratamento de leishmanioses e infecções mediadas por microorganismos patogênicos intracelulares nos mamíferos e em particular no homem, nos caninos, nos felinos e nos eqüídeos, caracterizado pelo fato de que ele é composto por moléculas de excreção secreção provenientes de promastigotos de leishmania sp. produzidos em um meio sem germes e sem soro definido.
BRPI0210317A 2001-06-11 2002-05-30 complexo de vacina terapêutica destinado à prevenção ou ao tratamento de leishmanioses e infecções mediadas por microorganismos patogênicos intracelulares nos mamíferos BRPI0210317C1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0107606A FR2825633B1 (fr) 2001-06-11 2001-06-11 Complexe vaccinal therapeutique destine a la prevention et au traitement des leishmanioses et des infections a microorganismes pathogenes intracellulaires chez le mammifere
PCT/FR2002/001823 WO2002100430A1 (fr) 2001-06-11 2002-05-30 Complexe vaccinal destine a la prevention et au traitement des leishmanioses

Publications (4)

Publication Number Publication Date
BR0210317A BR0210317A (pt) 2004-08-10
BRPI0210317B1 BRPI0210317B1 (pt) 2018-09-11
BRPI0210317B8 true BRPI0210317B8 (pt) 2018-10-09
BRPI0210317C1 BRPI0210317C1 (pt) 2021-05-25

Family

ID=8864170

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0210317A BRPI0210317C1 (pt) 2001-06-11 2002-05-30 complexo de vacina terapêutica destinado à prevenção ou ao tratamento de leishmanioses e infecções mediadas por microorganismos patogênicos intracelulares nos mamíferos

Country Status (10)

Country Link
US (1) US20060073170A1 (pt)
EP (1) EP1395282B1 (pt)
AT (1) ATE321568T1 (pt)
BR (1) BRPI0210317C1 (pt)
CY (1) CY1105309T1 (pt)
DE (1) DE60210276T2 (pt)
ES (1) ES2260440T3 (pt)
FR (1) FR2825633B1 (pt)
PT (1) PT1395282E (pt)
WO (1) WO2002100430A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8968749B2 (en) * 2006-07-21 2015-03-03 Universidade Federal De Minas Gerais—Ufmg Vaccine composition and immunization method
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
US20110129499A1 (en) 2008-05-19 2011-06-02 Paulo Maciag Dual delivery system for heterologous antigens
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
ES2595207T3 (es) * 2010-05-07 2016-12-28 Virbac Composición de vacuna para prevenir o tratar la leishmaniosis
WO2012138377A2 (en) * 2010-10-01 2012-10-11 Trustees Of The University Of Pennsylvania The use of listeria vaccine vectors to reverse vaccine unresponsiveness in parasitically infected individuals
CA2829960A1 (en) 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
WO2013138337A1 (en) 2012-03-12 2013-09-19 Advaxis Suppressor cell function inhibition following listeria vaccine treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206252A (en) * 1977-04-04 1980-06-03 Gordon Roy G Deposition method for coating glass and the like
US5599387A (en) * 1993-02-16 1997-02-04 Ppg Industries, Inc. Compounds and compositions for coating glass with silicon oxide
FR2705358B1 (fr) * 1993-05-13 1995-08-04 Orstom Procédé de culture in vitro de différents stades de parasites tissulaires, stades parasitaires obtenus et applications biologiques.
AU5820199A (en) * 1998-09-17 2000-04-03 Libbey-Owens-Ford Co. Heat strengthened coated glass article and method for making same
US6342925B1 (en) * 1999-01-15 2002-01-29 Sharp Laboratories Of America, Inc. Automatic audio and video parameter adjustment
DE60143927D1 (de) * 2000-03-13 2011-03-10 Sony Corp Verfahren und vorrichtung zur erzeugung von kompakten metadateien für transcodierungshinweise
WO2002027472A1 (en) * 2000-09-27 2002-04-04 Thomson Licensing S.A. Architecture for optimizing audio and video output states for multimedia devices
US6967588B2 (en) * 2002-03-25 2005-11-22 Sony Corporation System and method for controlling a home entertainment system

Also Published As

Publication number Publication date
FR2825633A1 (fr) 2002-12-13
BRPI0210317C1 (pt) 2021-05-25
WO2002100430A1 (fr) 2002-12-19
EP1395282A1 (fr) 2004-03-10
ATE321568T1 (de) 2006-04-15
US20060073170A1 (en) 2006-04-06
CY1105309T1 (el) 2010-03-03
EP1395282B1 (fr) 2006-03-29
PT1395282E (pt) 2006-07-31
BRPI0210317B1 (pt) 2018-09-11
DE60210276D1 (de) 2006-05-18
FR2825633B1 (fr) 2005-12-16
DE60210276T2 (de) 2006-11-30
ES2260440T3 (es) 2006-11-01
WO2002100430B1 (fr) 2003-02-13
BR0210317A (pt) 2004-08-10

Similar Documents

Publication Publication Date Title
BR9909668A (pt) Uso de compostos de organofósforo para o tratamento terapêutico e profilático de infecções
BRPI0414435A (pt) métodos e reagentes para o tratamento de distúrbios imunoinflamatórios
DZ3500A1 (fr) Derives de phenethanolamine pour le traitement de maladies respiratoires
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
BR9609413A (pt) Formulações de dieta e farmacêuticas para a profilaxia e o tratamento de distúrbios gastrintestinais
BR0213100A (pt) Combinações para o tratamento de distúrbios imuniinflamatórios
BR0209812A (pt) Uso de osteopontina para o tratamento e/ou a prevenção de doenças neurológicas
BR0111892A (pt) Bis-arilsulfonas
BRPI0210317B8 (pt) complexo de vacina terapêutica destinado à prevenção ou ao tratamento de leishmanioses e infecções mediadas por microorganismos patogênicos intracelulares nos mamíferos
EP1037650A4 (en) METHOD AND COMPOSITIONS FOR TREATING AND PREVENTING STAPHYLOCOCCUS AUREUS INFECTIONS
EP0869801A4 (en) THERAPEUTIC AND DIAGNOSTIC AGENTS FOR TREATING MICROBIAL INFECTIONS
BR0211830A (pt) Dose única de azitromicina
BR9712141A (pt) Aplicação de 1-hifróxi-2-piridonas para tratamento de infecções cutâneas.
MY139368A (en) Novel cyclohexyl sulphones
BR0109496A (pt) Uso de bactéria do ácido láctico para o tratamento de peritonite
ATE236592T1 (de) Aufblasbare decke mit eingeformten öffnungen
BR9804749A (pt) Tratamento de purido.
MXPA02012857A (es) Uso de una formulacion elaborada de o que contiene al menos un suero de leche dismilado.
BR0210632A (pt) Tratamento de doença parasìtica
ES2093257T3 (es) Utilizacion de torasemida para la preparacion de medicamentos destinados al tratamiento de edemas cerebrales.
MA25852A1 (fr) Methode pour le traitement de l'inflammation.
BR0005061A (pt) Secreção de ácido gástrico
NO20031650D0 (no) Nye legemidler for leversykdommer
BR0309684A (pt) O tratamento de dor com ifendropil
BR0007491A (pt) Uso de 3-isoxazolidinonas e ácidos hidroxilâmicospara o tratamento de infecções

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/09/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/09/2018, OBSERVADAS AS CONDICOES LEGAIS. (CO) REFERENTE A RPI 2488 DE 11/09/2018, QUANTO AO NOME DO TITULAR.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/05/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 21A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2725 DE 28/03/2023 POR TER SIDO INDEVIDA, UMA VEZ QUE O PRAZO DE VALIDADE DA PATENTE TERMINOU EM 30/05/2022.

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 30/05/2022